Hardcover

Second Generation Cell and Gene-Based Therapies

Biological Advances, Clinical Outcomes and Strategies for Capitalisation

$419.49

  • Hardcover

    846 pages

  • Release Date

    9 February 2020

Check Delivery Options

Summary

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalizati

Book Details

ISBN-13:9780128120347
ISBN-10:0128120347
Author:Alain Vertes, Nathan J. Dowden, Devyn Smith, Nasib Qureshi
Publisher:Elsevier Science Publishing Co Inc
Imprint:Academic Press Inc
Format:Hardcover
Number of Pages:846
Release Date:9 February 2020
Weight:1.86kg
Dimensions:191mm x 235mm
A-Format
B-Format
C-Format
Second Generation Cell and Gene-Based Therapies by Alain Vertes - ISBN: 9780128120347
191 × 235 mm
A4
mm / in
About The Author

Alain Vertes

University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flanders-Artois• Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois). • Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.• Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche). • Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in 2010 in the field of regenerative medicine.• Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society• Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015). • Head of Operations & Strategy, Medicinal Sciences Division of R&D, Pfizer Inc.• Responsible for all cell & gene therapy products, as well as previously developing Pfizer’s Regenerative Medicine program.• PhD in Genetics from Harvard Medical School.• Adjunct faculty member at Northeastern University. Research Chemical/Biochemical Engineer, United States Department of Agriculture (USDA), Agricultural Research Service (ARS), National Center for Agricultural Utilization Research (NCAUR), Peoria, IL, USA.PhD (Chemical/Biological Engineering), PhD (Fermentation Technology)Fellow in American Institute of Chemical Engineers (AIChE), Society for Industrial Microbiology & Biotechnology (SIMB), and American Institute of Chemists (AIC).Co-Editor, Stem cells in Regenerative Medicine (Wiley, 2015)

Returns

This item is eligible for free returns within 30 days of delivery. See our returns policy for further details.